Radionuclide Therapy of HER2-Expressing Xenografts Using [
Affibody molecule
HER2
lutetium-177
radionuclide therapy
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
22 Apr 2023
22 Apr 2023
Historique:
received:
28
03
2023
revised:
16
04
2023
accepted:
20
04
2023
medline:
13
5
2023
pubmed:
13
5
2023
entrez:
13
5
2023
Statut:
epublish
Résumé
ABY-027 is a scaffold-protein-based cancer-targeting agent. ABY-027 includes the second-generation Affibody molecule Z
Identifiants
pubmed: 37173878
pii: cancers15092409
doi: 10.3390/cancers15092409
pmc: PMC10177614
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Swedish Cancer Society
ID : CAN 21 1485 Pj
Organisme : Swedish Cancer Society
ID : CAN 20 0893 Pj
Organisme : Swedish Research Council
ID : 2019-00994
Organisme : Ministry of Science and Higher Education of the Russian Federation
ID : 075-15-2022-1103
Références
Lancet. 2019 Aug 31;394(10200):793-804
pubmed: 31478503
Cancer Res. 2007 Mar 15;67(6):2773-82
pubmed: 17363599
Pharmaceutics. 2022 Nov 19;14(11):
pubmed: 36432709
Mol Pharm. 2018 Aug 6;15(8):3394-3403
pubmed: 29995421
J Clin Oncol. 2013 Nov 20;31(33):4222-8
pubmed: 24127446
Lancet Oncol. 2018 Oct;19(10):1372-1384
pubmed: 30217672
J Clin Oncol. 2018 Sep 10;36(26):2736-2740
pubmed: 29939838
Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):203-11
pubmed: 15629613
Pharmaceutics. 2022 May 20;14(5):
pubmed: 35631678
Trends Biotechnol. 2017 Aug;35(8):691-712
pubmed: 28514998
Clin Cancer Res. 2020 Aug 15;26(16):4180-4185
pubmed: 32217612
Cancer Res. 2007 Mar 1;67(5):2178-86
pubmed: 17332348
Cancer. 2012 Apr 15;118(8):1982-8
pubmed: 21887681
Int J Mol Med. 2007 Feb;19(2):285-91
pubmed: 17203203
J Nucl Med. 2022 Jul;63(7):1046-1051
pubmed: 34711617
Cancer Res. 2018 May 1;78(9):2419-2431
pubmed: 29686021
J Mol Biol. 2010 Apr 30;398(2):232-47
pubmed: 20226194
J Clin Oncol. 2017 Jan 10;35(2):141-148
pubmed: 28056202
Nat Rev Drug Discov. 2020 Sep;19(9):589-608
pubmed: 32728208
J Nucl Med. 2022 Jun;63(6):840-846
pubmed: 34503960
J Nucl Med. 2022 Jan;63(1):5-13
pubmed: 34503958
Br J Cancer. 2020 Mar;122(5):603-612
pubmed: 31839676
Lancet. 2017 Jun 17;389(10087):2415-2429
pubmed: 27939064
J Biol Chem. 2002 Sep 20;277(38):35035-43
pubmed: 12119302
CA Cancer J Clin. 2022 Mar;72(2):165-182
pubmed: 34767258
Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15039-44
pubmed: 20696930
Pharmaceutics. 2021 Jun 07;13(6):
pubmed: 34200197
Mol Imaging. 2014;13:
pubmed: 25249017
Eur J Nucl Med Mol Imaging. 2021 May;48(5):1570-1584
pubmed: 33433699
N Engl J Med. 2017 Jul 13;377(2):122-131
pubmed: 28581356
Theranostics. 2016 Jan 01;6(2):262-71
pubmed: 26877784
Biomaterials. 2021 Jan;266:120381
pubmed: 33120197
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
Eur J Nucl Med Mol Imaging. 2009 Apr;36(4):692-701
pubmed: 19066886
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
FEBS Lett. 2010 Jun 18;584(12):2670-80
pubmed: 20388508
Cancers (Basel). 2020 Dec 30;13(1):
pubmed: 33396753
Appl Radiat Isot. 2006 Aug;64(8):901-5
pubmed: 16618544
J Nucl Med. 2018 Jul;59(7):1092-1098
pubmed: 29439013
J Nucl Med. 2013 Jun;54(6):961-8
pubmed: 23528382
Nat Rev Drug Discov. 2023 Feb;22(2):101-126
pubmed: 36344672
Protein Eng Des Sel. 2008 Aug;21(8):515-27
pubmed: 18499681